Sponsor or institution

Clinical trials and research at CSPC Megalith Biopharmaceutical Co.,Ltd.

• 11Clinical trials
• 1New in 30 days
• 1Country

Newest trials

All recruiting trials (11)

• SYS6010 plus Enlonstobart for recurrent or metastatic nasopharyngeal cancer in patients who have not had prior systemic therapy

  This trial tests whether SYS6010 with Enlonstobart works better than Tislelizumab with gemcitabine and cisplatin for people whose recurrent or metastatic nasopharyngeal cancer has not yet received systemic treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Guangzhou, Guangzhou · NCT07925021

• SYS6041: a first-in-human test in adults with advanced solid tumors

  This first-in-human trial tests SYS6041 in adults with advanced solid tumors to see if it is safe, how it behaves in the body, and whether it shows any signs of shrinking tumors.

  Recruiting Phase 1/2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Shanghai, Shanghai Municipality · NCT07744763

• SYS6041 in combination therapy for recurrent ovarian cancer

  This study tests SYS6041 combined with other cancer drugs in adults whose ovarian cancer has come back to see if it’s safe and possibly effective.

  Recruiting Phase 2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Shanghai, Shanghai Municipality · NCT07714668

• SYS6043 plus standard chemo vs standard chemo in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer

  This study tests SYS6043 against the doctor’s choice chemotherapy in adults with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer to see which treatment works better.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Beijing, Beijing Municipality · NCT07708753

• SYS6023 in combination with KN026 or HB1901 for advanced breast cancer

  This phase II study tests SYS6023 plus another agent to see if it is safe and may help people with unresectable or metastatic breast cancer.

  Recruiting Phase 2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Harbin, Heilonjiang · NCT07597629

• SYS6043 treatment for advanced or metastatic solid tumors

  We will test SYS6043, a B7‑H3‑targeted antibody‑drug conjugate, in adults with advanced or metastatic solid tumors who have progressed on or are intolerant of standard therapies.

  Recruiting Phase 1/2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Beijing, Beijing Municipality · NCT07415863

• SYS6010 combined with Enlonstobart for recurrent or metastatic head and neck squamous cell carcinoma

  This trial will test whether giving SYS6010 together with Enlonstobart can help people aged 18–75 who have recurrent or metastatic head and neck squamous cell carcinoma and are not candidates for surgery or chemoradiotherapy.

  Recruiting Phase 2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Shanghai, Shanghai Municipality · NCT07254585

• SYS6023 treatment for advanced solid tumors

  This trial tries SYS6023, given by IV every three weeks, in adults with advanced solid tumors to see if it is safe, how the body handles it, and whether it can shrink tumors.

  Recruiting at 2 sites Phase 1 CSPC Megalith Biopharmaceutical Co.,Ltd. · Harbin, Heilongjiang and 1 other locations · NCT07110883

• SYS6040 injection for patients with advanced solid tumors

  This study is testing a new injection called SYS6040 to see if it is safe and effective for people with advanced solid tumors who haven't had success with other treatments.

  Recruiting Phase 1 CSPC Megalith Biopharmaceutical Co.,Ltd. · Changchuan, Jilin · NCT06970795

• Evaluating SYS6005 for advanced malignant tumors

  This study is testing a new treatment called SYS6005 to see if it is safe and effective for people with advanced malignant tumors.

  Recruiting Phase 1 CSPC Megalith Biopharmaceutical Co.,Ltd. · Tianjin · NCT06958679

• SYS6010 versus platinum chemotherapy for EGFR‑mutated advanced NSCLC

  This trial tests whether SYS6010 works better and is safe compared with platinum‑based chemotherapy for people whose EGFR‑mutated advanced non‑small cell lung cancer has progressed after EGFR TKI treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Shanghai, Shanghai Municipality · NCT06927986

Quick answers

How many clinical trials run by CSPC Megalith Biopharmaceutical Co.,Ltd. are recruiting right now?

11, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 3: 3, Phase 1: 3, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →